Table 2.
Demographic and Baseline Characteristics
| Placebo (n = 508) | ATX-101 (n = 514) | |
|---|---|---|
| Age, mean (SD), years | 48.5 (9.2) | 48.8 (9.3) |
| Sex, female, % | 85.0 | 84.4 |
| Race, % | ||
| White | 88.4 | 85.6 |
| Black | 6.7 | 9.3 |
| Asian | 2.0 | 2.1 |
| BMI, mean (SD), kg/m2 | 29.3 (4.3) | 29.2 (4.6) |
| CR-SMFRS grade, % | ||
| Moderate (2)/severe (3) | 51.4/48.2 | 49.8/50.0 |
| PR-SMFRS grade, % | ||
| Moderate amount (2)/large amount (3) | 62.2/37.4 | 63.4/36.4 |
| Fitzpatrick skin type, % | ||
| I-III/IV-VI | 71.5/28.5 | 68.1/31.9 |
| SMSLG grade, % | ||
| None (1)–mild (2) | 82.9 | 83.7 |
| Moderate (3)–severe (4) | 16.7 | 16.1 |
BMI, body mass index; CR-SMFRS, Clinician-Reported Submental Fat Rating Scale; PR-SMFRS, Patient-Reported Submental Fat Rating Scale; SD, standard deviation; SMSLG, Submental Skin Laxity Grade.